Literature DB >> 27114326

Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study.

Nicholas R Latimer1, Keith R Abrams2, Paul C Lambert2,3, James P Morden4, Michael J Crowther2,3.   

Abstract

When patients randomised to the control group of a randomised controlled trial are allowed to switch onto the experimental treatment, intention-to-treat analyses of the treatment effect are confounded because the separation of randomised groups is lost. Previous research has investigated statistical methods that aim to estimate the treatment effect that would have been observed had this treatment switching not occurred and has demonstrated their performance in a limited set of scenarios. Here, we investigate these methods in a new range of realistic scenarios, allowing conclusions to be made based upon a broader evidence base. We simulated randomised controlled trials incorporating prognosis-related treatment switching and investigated the impact of sample size, reduced switching proportions, disease severity, and alternative data-generating models on the performance of adjustment methods, assessed through a comparison of bias, mean squared error, and coverage, related to the estimation of true restricted mean survival in the absence of switching in the control group. Rank preserving structural failure time models, inverse probability of censoring weights, and two-stage methods consistently produced less bias than the intention-to-treat analysis. The switching proportion was confirmed to be a key determinant of bias: sample size and censoring proportion were relatively less important. It is critical to determine the size of the treatment effect in terms of an acceleration factor (rather than a hazard ratio) to provide information on the likely bias associated with rank-preserving structural failure time model adjustments. In general, inverse probability of censoring weight methods are more volatile than other adjustment methods.

Entities:  

Keywords:  Treatment switching; health technology assessment; oncology; overall survival; prediction; survival analysis; time-to-event outcomes; treatment crossover

Mesh:

Year:  2016        PMID: 27114326     DOI: 10.1177/0962280216642264

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  13 in total

Review 1.  The need for increased pragmatism in cardiovascular clinical trials.

Authors:  Muhammad Shariq Usman; Harriette G C Van Spall; Stephen J Greene; Ambarish Pandey; Darren K McGuire; Ziad A Ali; Robert J Mentz; Gregg C Fonarow; John A Spertus; Stefan D Anker; Javed Butler; Stefan K James; Muhammad Shahzeb Khan
Journal:  Nat Rev Cardiol       Date:  2022-05-17       Impact factor: 49.421

2.  Routine Early Antibiotic Use in SymptOmatic Preterm Neonates: A Pilot Randomized Controlled Trial.

Authors:  J Lauren Ruoss; Catalina Bazacliu; Jordan T Russell; Diomel de la Cruz; Nan Li; Matthew J Gurka; Stephanie L Filipp; Richard A Polin; Eric W Triplett; Josef Neu
Journal:  J Pediatr       Date:  2020-09-23       Impact factor: 4.406

3.  Adjusting Overall Survival Estimates after Treatment Switching: a Case Study in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Konstantina Skaltsa; Cristina Ivanescu; Shevani Naidoo; Stefan Holmstrom; Nicholas R Latimer
Journal:  Target Oncol       Date:  2017-02       Impact factor: 4.493

4.  Estimating efficacy in trials with selective crossover.

Authors:  Adam R Brentnall; Peter Sasieni; Jack Cuzick
Journal:  Stat Med       Date:  2017-03-15       Impact factor: 2.373

5.  Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.

Authors:  N R Latimer; K R Abrams; U Siebert
Journal:  BMC Med Res Methodol       Date:  2019-03-29       Impact factor: 4.615

6.  Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?

Authors:  N R Latimer; I R White; K R Abrams; U Siebert
Journal:  Stat Methods Med Res       Date:  2018-06-25       Impact factor: 3.021

7.  Trends in the crossover of patients in phase III oncology clinical trials in the USA.

Authors:  Justin Yeh; Shruti Gupta; Sunny J Patel; Vamsi Kota; Achuta K Guddati
Journal:  Ecancermedicalscience       Date:  2020-11-13

8.  Adjustment for treatment changes in epilepsy trials: A comparison of causal methods for time-to-event outcomes.

Authors:  Susanna Dodd; Paula Williamson; Ian R White
Journal:  Stat Methods Med Res       Date:  2017-11-08       Impact factor: 3.021

9.  Improved two-stage estimation to adjust for treatment switching in randomised trials: g-estimation to address time-dependent confounding.

Authors:  N R Latimer; I R White; K Tilling; U Siebert
Journal:  Stat Methods Med Res       Date:  2020-03-30       Impact factor: 3.021

10.  Estimating the treatment effect in patients with gastric cancer in the presence of noncompliance.

Authors:  Malihe Safari; Hossein Mahjub; Habib Esmaeili; Sanambar Sadighi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.